COMP <GO>
SYK vs MRK // EV/EBITDA & P/E VALUATION
Stryker Corporation (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SYK 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
valuation
23.6x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYK VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYK | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.00% | 74.80% | -10.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.60% | 20.70% | -9.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 23.6x | 15.3x | +8.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.58% | 3.42% | +0.16 | SYK | /fcf-yield <GO> |
| Operating Margin | 19.50% | 34.30% | -14.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.90% | 28.10% | -15.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 1.30% | +9.90 | SYK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 2.26% | -1.19 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.46 | 5.19 | -0.73 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | SYK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 56.9 | -8.88 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.92 | +0.21 | SYK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.2x | 18.4x | +15.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $119.58B | $361.02B | -$241.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYK REV | MRK REV | SYK GROSS % | MRK GROSS % | SYK FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.12B | $65.01B | 64.0% | 74.8% | $4.28B | $12.36B |
| FY 2024 | $22.59B | $64.17B | 63.9% | 76.3% | $3.49B | $18.10B |
| FY 2023 | $20.50B | $60.12B | 44.0% | 44.0% | $2.79B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYK // BETA 1.13
MRK // BETA 0.92